Kimberly L Blackwell MD
Professor of Medicine and Assistant Professor in Radiation Oncology, Duke Department of Medicine, Durham, NCDr. Blackwell is the director of the Duke University breast cancer group where she supervises the clinical operations and the conduct of over 50 translational and therapeutic trials in breast cancer. She is well recognized as a national leader in early phase clinical trial design, early phase drug development, and translational biomarker development in breast cancer. She is currently a Susan G. Komen Research Scholar. She has been the principle investigator on over 40 clinical trials in metastatic breast cancer, and the co-investigator on multiple large correlative science projects. She was the principle investigator on the pre-clinical, phase 2, and phase 3 studies that led to the approval of lapatinib for the treatment of HER2 overexpressing breast cancer.
Disclosures
Kimberly L. Blackwell, MD serves as a consultant/advisory board member for Amgen Inc., Celgene Corp., Eli Lilly and Co., Genentech, USA, F. Hoffmann-La Roche Ltd., Novartis Pharmaceuticals, Inc., Pfizer, Inc., Spectrum Pharmaceuticals, Inc., Advaxis, Inc., Bayer Healthcare Pharmaceuticals, Inc., Puma Biotechnology, Inc., Incyte Corp., and Sandoz, Inc.; and serves as a principal investigator where her institution receives research grant support from Novartis Pharmaceuticals, Inc., Pfizer, Inc., Genentech, USA, and Celgene Corp.Recent Contributions to PracticeUpdate:
- Dr. Kimberly Blackwell’s 2014 ASCO Abstract Recommendations—Breast Cancer: HER2/ER Disease
- Genomic Studies From SABCS 2013
- 2013 Top Stories in Oncology: This Was the Year for HER2-Positive Breast Cancer
- Frequently Asked Questions in Oncology: Metastatic Breast Cancer
- SABCS 2013 Recommended Abstracts: New Data on Breast Cancer Therapies
- The Role of Everolimus Right Now—Advanced Breast Cancer
- Dr. Kimberly Blackwell's ASCO Take-Home Messages—Metastatic Breast Cancer
- Dr. Kimberly Blackwell Discusses T-DM1